NITO

N2OFF, Inc. (NITO) | Rumor.io

N2OFF

NITO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,995

Bullish sentiment (50-day avg)95%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NITO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Feb 25

$NITO has rebranded as Nexentis Technologies, a company focused on AI and data-driven computational biotech, particularly in mitochondrial biotech.
The rebranding is seen as a catalyst for the stock, with the market responding positively to the new direction.
The stock is considered thin and reactive, with a break above resistance potentially triggering a move.

Generated by AI

Sentiment

Of the messages about NITO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.8% -4.5
Bearish	—	—	—	20.2% +4.5

Bullish· Feb 25

$NITO is poised for a breakout after a rebrand catalyst, with a new focus on AI and data-driven computational biotech.
The stock is building a base and is thin and reactive, making it susceptible to price movements with minimal liquidity.
$NITO is showing signs of a strong close, with buyers re-entering the market and price lifting after a quiet period.

Bearish· Jan 22

$NITO is experiencing a significant drop in volume, with 362 times the average volume and declining, suggesting potential manipulation.
Investors who have previously touched Tel Aviv-based stocks, including $NITO, have seen them tank by market open, indicating a pattern of poor performance.
$NITO's short position is facing a potential loss, with the stock moving against the predicted target price of $2.50 or below.

Generated by AI

Topics

Of the messages about NITO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	82.54%
Controversies	—	—	—	1.37%
Earnings	—	—	—	0%
Macro	—	—	—	0.12%
Technical Analysis	—	—	—	15.96%

Announcements· Jan 22

N2OFF Inc announced positive preliminary in vitro results from its MitoCareX Bio mitochondrial carrier small-molecule platform, showing inhibition of pro-inflammatory responses in human immune cells.
The results support further in vivo validation and lead-compound optimization across multiple inflammatory metabolic disease indications, with MitoCareX's MITOLINE algorithm enabling reliable 3D comparative models of mitochondrial transporter proteins.
N2OFF has completed its acquisition of biotechnology company MitoCareX Bio, entering the cancer treatment field, while its core renewable energy business is also expanding with solar projects in Germany and energy storage investments in Italy.

Technical Analysis· May 5

$NITO is expected to break its daily high and is considered bullish.
The stock's uptrend remains intact, with potential pullbacks at key resistance levels and a possible long-term seal broken from its trendline.
The 5-minute chart shows a healthy pullback, and the stock is expected to consolidate until a new 15-minute candle is formed, potentially leading to a significant price movement.

Generated by AI

Community

Of the messages about NITO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.65%
Newcomers	—	—	—	61.35%

Jan 22

New investors are discussing the positive in vitro results announced by N2OFF, Inc., specifically the inhibition of pro-inflammatory responses in human immune cells using its proprietary discovery platform.
The newcomers are focusing on the potential implications of N2OFF's preliminary data for further preclinical development and the overall value of the stock.
Investors are also looking at the current price and volume of NITO, with some noting its volatility and high trading volume.

Generated by AI

News

N2OFF Announces Potential to Maximize Investment Opportunity Following New Regulation in Germany

New German regulation, Section 8a of the Renewable Energy Sources Act – EEG, allows expanded use of grid infrastructure, enabling high-value battery...

1mo agoBarchart.com

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the

1mo agoBarchart.com

Also Discussed

Investors talking about NITO also mention

#	Name	Attention
1	Carmell CorporationCTCX	0%0
2	Nvni Group LimitedNVNI	0%0
3	Kuke Music Holding Limited American Depositary ReceiptKUKE	0%0
4	ZCAR - Zoomcar Holdings, Inc.	——
5	Aclarion, Inc.ACON	0%0
6	Jiade Ltd. Class A Ordinary SharesJDZG	0%0
7	NUKK - Nukkleus Inc.	——
8	AGM Group Holdings IncAGMH	0%0
9	AREB - American Rebel Holdings, Inc.	——
10	MicroAlgo Inc.MLGO	0%new

N2OFF, Inc.

Location

Social

What share of all stock conversation is about NITO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Feb 25

$NITO has rebranded as Nexentis Technologies, a company focused on AI and data-driven computational biotech, particularly in mitochondrial biotech.
The rebranding is seen as a catalyst for the stock, with the market responding positively to the new direction.
The stock is considered thin and reactive, with a break above resistance potentially triggering a move.

Generated by AI

Sentiment

Of the messages about NITO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.8% -4.5
Bearish	—	—	—	20.2% +4.5

Bullish· Feb 25

$NITO is poised for a breakout after a rebrand catalyst, with a new focus on AI and data-driven computational biotech.
The stock is building a base and is thin and reactive, making it susceptible to price movements with minimal liquidity.
$NITO is showing signs of a strong close, with buyers re-entering the market and price lifting after a quiet period.

Bearish· Jan 22

$NITO is experiencing a significant drop in volume, with 362 times the average volume and declining, suggesting potential manipulation.
Investors who have previously touched Tel Aviv-based stocks, including $NITO, have seen them tank by market open, indicating a pattern of poor performance.
$NITO's short position is facing a potential loss, with the stock moving against the predicted target price of $2.50 or below.

Generated by AI

Topics

Of the messages about NITO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	82.54%
Controversies	—	—	—	1.37%
Earnings	—	—	—	0%
Macro	—	—	—	0.12%
Technical Analysis	—	—	—	15.96%

Announcements· Jan 22

N2OFF Inc announced positive preliminary in vitro results from its MitoCareX Bio mitochondrial carrier small-molecule platform, showing inhibition of pro-inflammatory responses in human immune cells.
The results support further in vivo validation and lead-compound optimization across multiple inflammatory metabolic disease indications, with MitoCareX's MITOLINE algorithm enabling reliable 3D comparative models of mitochondrial transporter proteins.
N2OFF has completed its acquisition of biotechnology company MitoCareX Bio, entering the cancer treatment field, while its core renewable energy business is also expanding with solar projects in Germany and energy storage investments in Italy.

Technical Analysis· May 5

$NITO is expected to break its daily high and is considered bullish.
The stock's uptrend remains intact, with potential pullbacks at key resistance levels and a possible long-term seal broken from its trendline.
The 5-minute chart shows a healthy pullback, and the stock is expected to consolidate until a new 15-minute candle is formed, potentially leading to a significant price movement.

Generated by AI

Community

Of the messages about NITO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.65%
Newcomers	—	—	—	61.35%

Jan 22

New investors are discussing the positive in vitro results announced by N2OFF, Inc., specifically the inhibition of pro-inflammatory responses in human immune cells using its proprietary discovery platform.
The newcomers are focusing on the potential implications of N2OFF's preliminary data for further preclinical development and the overall value of the stock.
Investors are also looking at the current price and volume of NITO, with some noting its volatility and high trading volume.

Generated by AI

N2OFF

Social

Feb 25

Bullish· Feb 25

Bearish· Jan 22

Announcements· Jan 22

Technical Analysis· May 5

Jan 22

N2OFF Announces Potential to Maximize Investment Opportunity Following New Regulation in Germany

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Also Discussed

N2OFF, Inc.

Company Information

Location

N2OFF Announces Potential to Maximize Investment Opportunity Following New Regulation in Germany

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Also Discussed

Social

Feb 25

Bullish· Feb 25

Bearish· Jan 22

Announcements· Jan 22

Technical Analysis· May 5

Jan 22